During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?